TALOPH(600222)2022-04-19 16:00Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of RMB 5,995,375.55, a decrease of 79.50% compared to RMB 29,240,862.39 in 2020[5]. - The company's operating revenue for 2021 was RMB 1,604,516,940.00, representing a year-on-year increase of 13.23% from RMB 1,417,097,311.59 in 2020[21]. - The net cash flow from operating activities increased by 35.72% to RMB 99,655,159.11 in 2021, compared to RMB 73,427,546.30 in 2020[21]. - The total assets of the company as of the end of 2021 were RMB 3,783,772,407.22, an increase of 11.64% from RMB 3,389,394,715.08 at the end of 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 36,179,012.56, a significant increase of 159.11% compared to RMB 13,962,693.07 in 2020[21]. - Basic earnings per share (EPS) fell by 80.00% to RMB 0.0107, while diluted EPS remained the same[22]. - The weighted average return on equity (ROE) decreased by 1.73 percentage points to 0.37%[22]. - The company reported a significant loss of RMB 30.18 million from non-recurring gains and losses, impacting overall profitability[27]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.10 per share, totaling RMB 5,630,401.76, which accounts for 93.91% of the net profit attributable to shareholders for 2021[5]. - For the 2021 fiscal year, the company plans to distribute a cash dividend of CNY 0.10 per share (including tax), amounting to CNY 5,630,401.76, which represents 93.91% of the net profit attributable to shareholders of the parent company[172]. Business Growth and Strategy - The company's operating revenue increased by 13.23% year-on-year, driven by a 35.74% growth in pharmaceutical R&D services and a 19.31% increase in traditional Chinese medicine products[23]. - The company is focusing on expanding its market presence and enhancing brand promotion for its traditional Chinese medicine products[23]. - The company is actively expanding its market presence by integrating existing traditional Chinese medicine products and increasing marketing investments in targeted product combinations[34]. - The company aims to enhance product quality through strict adherence to production standards and quality management practices[49]. - The company is committed to expanding its market presence and enhancing brand influence through strategic partnerships and marketing initiatives[56]. Research and Development - The company has 906 personnel in the R&D team, with 23.62% holding master's or doctoral degrees, indicating a strong talent pool[36]. - The company has established multiple platforms for drug research, focusing on high-end formulations and innovative drug research, including preclinical and clinical trial services[57]. - The company has initiated 56 new research projects in high-end generic and innovative drugs, bringing the total number of ongoing projects to 267[103]. - The company is focusing on high-barrier therapeutic areas such as cardiovascular, anti-tumor, and digestive system drugs, aligning R&D efforts with market demand[103]. - The company is conducting clinical research on TLZ0005, a new drug for breast disease, which is currently in the clinical research phase[104]. Environmental Responsibility - The company was listed as a key pollutant discharge unit in Zhengzhou for 2021, with strict adherence to national standards for pollutant treatment and discharge[184]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties from environmental protection authorities[185]. - The company has implemented a comprehensive environmental monitoring plan, with third-party testing confirming that all pollutants are within regulatory limits[192]. - The company emphasizes a low-carbon production philosophy, advocating for resource conservation and green practices among employees[197]. Governance and Management - The governance structure of the company is robust, ensuring compliance with laws and regulations while protecting shareholder interests[134]. - The company maintains transparent communication with investors, ensuring their rights are protected and fostering good investor relations[136]. - The company completed the election of the ninth board of directors and the ninth supervisory board on February 25, 2022, with new appointments including Yin Hui as chairman and Luo Jianchao as general manager[143]. - The company has proposed to allocate profits for the year 2020, indicating a focus on shareholder returns[139]. - The company has established a comprehensive human resources management system, including salary and welfare, performance evaluation, training management, and promotion systems[169]. Market Trends and Industry Insights - The Chinese CRO market is expected to grow at a compound annual growth rate (CAGR) of 20.22% from 2020 to 2030, reaching a market size of approximately 329.2 billion yuan by 2030[42]. - The global CRO market is projected to reach $168.9 billion by 2030, with a CAGR of 9.95% from 2020 to 2030[42]. - The pharmaceutical manufacturing industry achieved operating revenue of 2,928.85 billion yuan in 2021, growing by 20.1% year-on-year, indicating a robust industry trend[40]. - The ongoing reforms in the medical insurance system are expected to further support the development of TCM services and products[47]. Community Engagement - The company donated over 1.5 million yuan worth of medicines to support disaster relief efforts following severe flooding[198]. - The company aims to support rural economic development by promoting standardized planting techniques and processing projects for traditional Chinese medicine[199].